Chimeric secures $1.62M funding against FY26 R&D tax incentive
Chimeric Therapeutics (ASX: CHM) has received $1,620,000 from Endpoints Capital under a funding facility secured against its anticipated FY26 Research and Development Tax Incentive (RDTI).
It arrives while the Company undertakes its previously announced Strategic Review.
According to the announcement, the $1.62M will support ongoing Phase 1/2 clinical trial activities and general working capital, providing near-term operational support for the clinical-stage cell therapy business.
When big ASX news breaks, our subscribers know first
How the funding facility works
The agreement with Endpoints Capital provides Chimeric with early access to a portion of its anticipated FY26 RDTI. The key terms disclosed in the announcement are as follows:
-
Amount received: $1.62M
-
Secured against the anticipated FY26 RDTI to be received from the Australian Taxation Office
-
Interest charged at a commercial rate
-
Repayment timed to follow the anticipated receipt of the FY26 RDTI, and due by 31 December 2026
-
The facility can be repaid at any time prior to that date, subject to the terms of the facility
The announcement also confirmed that the principal and interest under the earlier R&D facility with Radium Capital, announced on 2 March 2026, has been repaid and discharged. This represents a transition from one RDTI-backed facility to another, with the new Endpoints Capital arrangement replacing the previous funding line.
The earlier Radium Capital facility, announced in March 2026, provided $1.785 million against the same RDTI mechanism and has now been fully repaid and discharged, with the Endpoints Capital arrangement serving as its replacement.
| Term | Detail |
|---|---|
| Provider | Endpoints Capital |
| Amount received | $1.62M |
| Security | Anticipated FY26 RDTI |
| Interest | Commercial rate |
| Repayment due | 31 December 2026 |
Understanding the R&D Tax Incentive
The Australian Government RDTI programme provides companies engaging in eligible research and development activities with a refundable tax offset of up to 43.5%.
Why this matters during the Strategic Review
The announcement explicitly notes that the ability to access funding to support initiatives is a key requirement of the ongoing Strategic Review. The Endpoints Capital facility therefore secures near-term operational continuity for the clinical pipeline while the Board assesses strategic options.
The Chimeric Therapeutics Strategic Review, launched in June 2026 with independent adviser Hawkesbury Partners appointed to evaluate partnerships, licensing, mergers, and asset sales, provides the broader context within which this funding decision sits.
The Company has not disclosed the outcome of the Strategic Review, and no speculation on its direction is possible from the source.
Inside Chimeric’s clinical pipeline
Chimeric holds a diversified portfolio of cell therapies with 4 clinical stage programs across multiple disease areas in oncology. The newly received funding supports the continued advancement of this pipeline. Its two lead assets are:
-
CHM CDH17 — a first-in-class, 3rd generation CDH17 CAR T invented at the University of Pennsylvania, currently being studied in a Phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours initiated in 2024.
-
CHM CORE-NK — a potentially best-in-class, clinically validated NK cell platform, with two additional Phase 1B clinical trials investigating CORE-NK in combination regimens initiated.
From the CORE-NK platform, Chimeric has also initiated development of next generation NK and CAR NK assets, extending the reach of its allogeneic cell therapy work.
Chimeric Therapeutics Board of Directors
The $1.62M received by the Company will support the ongoing Phase 1/2 clinical trial activities and general working capital.
What comes next
The near-term timeline centres on repayment of the Endpoints Capital facility, which is due by 31 December 2026 and timed to follow receipt of the FY26 RDTI from the Australian Taxation Office.
The ongoing Strategic Review remains the key forward-looking item for investors to watch. For now, the position is straightforward: funding received, the earlier Radium Capital facility discharged, and clinical trials continuing, with no outcome disclosed for the Strategic Review beyond what the source states.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.